Suppr超能文献

相似文献

1
Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase.
Arterioscler Thromb Vasc Biol. 2009 Aug;29(8):1172-8. doi: 10.1161/ATVBAHA.109.185918. Epub 2009 May 14.
3
S6 kinase 1 knockout inhibits uninephrectomy- or diabetes-induced renal hypertrophy.
Am J Physiol Renal Physiol. 2009 Sep;297(3):F585-93. doi: 10.1152/ajprenal.00186.2009. Epub 2009 May 27.
4
Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis.
Kidney Int. 2007 Apr;71(8):771-7. doi: 10.1038/sj.ki.5002112. Epub 2007 Feb 14.
6
Role for Target of Rapamycin (mTOR) Signal Pathway in Regulating Neuronal Injury after Intracerebral Hemorrhage.
Cell Physiol Biochem. 2017;41(1):145-153. doi: 10.1159/000455983. Epub 2017 Jan 18.
7
Pharmacological inhibition of S6K1 increases glucose metabolism and Akt signalling in vitro and in diet-induced obese mice.
Diabetologia. 2016 Mar;59(3):592-603. doi: 10.1007/s00125-015-3839-6. Epub 2016 Jan 5.
8
Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway.
Cancer Res. 2010 Mar 1;70(5):1951-9. doi: 10.1158/0008-5472.CAN-09-3201. Epub 2010 Feb 16.
10
Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.
Breast Cancer Res Treat. 2012 Dec;136(3):673-82. doi: 10.1007/s10549-012-2298-8. Epub 2012 Oct 21.

引用本文的文献

2
Cognitive Impairment in Multiple Sclerosis.
Bioengineering (Basel). 2023 Jul 23;10(7):871. doi: 10.3390/bioengineering10070871.
4
Gastric Cancer Vascularization and the Contribution of Reactive Oxygen Species.
Biomolecules. 2023 May 25;13(6):886. doi: 10.3390/biom13060886.
5
Cellular Metabolism: A Fundamental Component of Degeneration in the Nervous System.
Biomolecules. 2023 May 11;13(5):816. doi: 10.3390/biom13050816.
8
Protrudin regulates FAK activation, endothelial cell migration and angiogenesis.
Cell Mol Life Sci. 2022 Apr 4;79(4):220. doi: 10.1007/s00018-022-04251-z.
10
Substrate stiffening promotes VEGF-A functions via the PI3K/Akt/mTOR pathway.
Biochem Biophys Res Commun. 2022 Jan 1;586:27-33. doi: 10.1016/j.bbrc.2021.11.030. Epub 2021 Nov 13.

本文引用的文献

2
Chapter 3. The adenoviral vector angiogenesis/lymphangiogenesis assay.
Methods Enzymol. 2008;444:43-64. doi: 10.1016/S0076-6879(08)02803-6.
3
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Lancet. 2008 Aug 9;372(9637):449-56. doi: 10.1016/S0140-6736(08)61039-9. Epub 2008 Jul 22.
4
Progression-free survival as endpoint in metastatic RCC?
Lancet. 2008 Aug 9;372(9637):427-9. doi: 10.1016/S0140-6736(08)61040-5. Epub 2008 Jul 22.
5
6
VEGF-A and the induction of pathological angiogenesis.
Annu Rev Pathol. 2007;2:251-75. doi: 10.1146/annurev.pathol.2.010506.134925.
8
Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression.
Cancer Res. 2007 Jun 1;67(11):5070-5. doi: 10.1158/0008-5472.CAN-06-3341.
9
Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting.
J Exp Med. 2007 Jun 11;204(6):1431-40. doi: 10.1084/jem.20062642. Epub 2007 May 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验